Download PDF
Pharmacopsychiatry 2010; 43(2): 58-65
DOI: 10.1055/s-0029-1239540
Original Paper

© Georg Thieme Verlag KG Stuttgart · New York

Serum Concentrations, Therapeutic Response and Side Effects in Children and Adolescents with Impulsive-Aggressive Symptoms during Risperidone Therapy

K. Klampfl1 , R. Taurines1 , A. Preuss1 , R. Burger4 , S. Rothenhöfer2 , Ch. Wewetzer2 , B. Pfuhlmann4 , J. Fegert3 , M. Gerlach1 , 4 , C. Mehler-Wex3
  • 1Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany
  • 2Clinics of City Cologne GmbH, Child and Adolescent Psychiatry and Psychotherapy, Cologne, Germany
  • 3Department of Child and Adolescent Psychiatry and Psychotherapy, University of Ulm, Ulm Germany
  • 4Laboratory for Therapeutic Drug Monitoring, Clinics for Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany
Further Information

Publication History

received 29.05.2009 revised 25.07.2009

accepted 06.08.2009

Publication Date:
10 December 2009 (online)

Also available at
    Permissions and Reprints

Abstract

Introduction: The aim of this prospective naturalistic study was to examine for the first time the relationship between dosage, serum concentration and clinical outcome in children and adolescents with impulsive-aggressive symptoms during risperidone therapy.

Methods: Steady state trough serum concentrations of risperidone and 9-hydroxyrisperidone (the active moiety) were measured in 103 subjects. The therapeutic effect was assessed by the clinical global impression improvement subscale and side effects by the Udvalg for Kliniske Undersogelser-side effect rating scale.

Results: We found a linear relationship between the risperidone dose and the serum concentration of the active moiety (Spearman ρ=0.53) and no correlation between the serum concentration and either the therapeutic effect or side effects. There was no effect of gender and co-medication.

Discussion: This study has the typical limitations of naturalistic studies, therefore our results should be interpreted with caution. Based on the serum concentrations at the therapeutically effective dose range (0.25–1.5 mg/day) we obtained first information on a possibly appropriate therapeutic serum range for the risperidone treatment of children and adolescents with impulsive-aggressive symptoms. Further studies with greater sample sizes are needed to validate our results and to examine the influence of genetic polymorphisms on the serum concentration of risperidone.

References

  • 1 Aman MG, Tassé MJ, Rojahn J. et al . The Nisonger CBRF: A child behavior rating form for children with developmental disabilities.  Research in Developmental Disabilities. 1996;  17 41-57
    CrossrefPubMedGoogle Scholar
  • 2 Aman MG, De Smedt G, Derivan A. et al . Risperidone Disruptive Behavior Study Group   Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.  Am J Psychiatry. 2002;  159 1337-1346
    CrossrefPubMedGoogle Scholar
  • 3 Aman MG, Binder C, Turgay A. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.  J Child Adolesc Psychopharmacol. 2004;  14 243-254
    CrossrefPubMedGoogle Scholar
  • 4 APA .Diagnostic and Statistical Manual of Mental Disorders. 4th Edition (DSM-IV), Washington DC, APA 1994
    PubMed
  • 5 Aravagiri M, Marder SR, Wirshing D. et al . Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: Simultaneous determination by a high performance liquid chromatography with electrochemical detection.  Pharmacopsychiatry. 1998;  31 102-109
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Aravagiri M, Marder SR, Nuechterlein KH. et al . Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone.  Ther Drug Monit. 2003;  25 657-664
    CrossrefPubMedGoogle Scholar
  • 7 Baumann P, Hiemke C, Ulrich S. et al . The AGNP-TDM expert group consensus guidelines. Therapeutic drug monitoring in psychiatry.  Pharmacopsychiatry. 2004;  37 243-265
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Carlsson A. The neurochemical circuitry of schizophrenia.  Pharmacopsychiatry. 2006;  39 10-14
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Clement HW, Taram C, Fleischhaker C. et al .Bestimmung und Wirkung der Höhe des Serumspeigels von Risperidon und 9-Hydroxyrisperidon in einem Kollektiv von Kindern und Jugendlichen. In: Schulte-Markwort M, editor Psychosomatik- Kinder- und Jugendpsychiatrie als interdisziplinäres Fach, Medizinisch Wissenschaftliche Verlagsgesellschaft 2009
    PubMed
  • 10 De Leon J, Susce MT, Pan RM. et al . A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.  Pharmacopsychiatry. 2007;  40 93-102
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Farde L, Nordström AL, Wiesel FA. et al . Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine Relation to extrapyramidal side effects.  Arch Gen Psychiatry. 1992;  49 538-544
    Google Scholar
  • 12 Findling RL, McNamara NK, Branicky LA. et al . A double-blind pilot study of risperidone in the treatment of conduct disorder.  J Am Acad Child Adolesc Psychiatry. 2000;  39 509-516
    CrossrefPubMedGoogle Scholar
  • 13 Findling RL. Dosing of atypical antipsychotics in children and adolescents.  Primary Care Companion J Clin Psychiatry. 2003;  5 10-13
    PubMedGoogle Scholar
  • 14 Findling RL. Atypical antipsychotic treatment of disruptive behaviour disorders in children and adolescents.  J Clin Psychiatry. 2008;  69 9-14
    CrossrefPubMedGoogle Scholar
  • 15 Gerlach M, Rothenhöfer S, Mehler-Wex C. et al . Therapeutic drug monitoring in child and adolescent psychiatry practical recommendations.  Z Kinder Jugendpsychiatr Psychother. 2006;  34 5-13
    CrossrefPubMedGoogle Scholar
  • 16 Gründer G, Fellows C, Janouschek H. et al . Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: An [18F]fallypride PET study.  Am J Psychiatry. 2008;  165 988-995
    CrossrefPubMedGoogle Scholar
  • 17 Guy W. ECDEU assessment manual. Rockville, National Institute of Mental Health 1976
    PubMed
  • 18 Heykants J, Huang ML, Mannens G. et al . The pharmacokinetics of risperidone in humans: A summary.  J Clin Psychiatry. 1994;  55 13-17
    PubMedGoogle Scholar
  • 19 Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.  Am J Psychiatry. 1999;  156 286-293
    PubMedGoogle Scholar
  • 20 Kirschbaum KM, Finger S, Vogel F. et al . High performance-liquid chromatography with column-switching and spectro–photometric detection for determination of risperidone and 9-hydroxyrisperidone in human serum.  Chromatographia. 2008;  67 321-324
    CrossrefPubMedGoogle Scholar
  • 21 Lingjaerde O, Ahlfors UG, Bech P. et al . The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients.  Acta Psychiatr Scand. 1987;  334 1-100
    PubMedGoogle Scholar
  • 22 Maughan B, Rowe R, Messer J. et al . Conduct disorder and oppositional defiant disorder in a national sample: Developmental epidemiology.  J Child Psychol Psychiatry. 2004;  45 609-621
    CrossrefPubMedGoogle Scholar
  • 23 Mauri MC, Volonteri LS, Colasanti A. et al . Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.  Clin Pharmacokinet. 2007;  46 359-388
    CrossrefPubMedGoogle Scholar
  • 24 McCracken JT, McGough J, Shah B. et al . Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems.  N Engl J Med. 2002;  347 314-321
    CrossrefPubMedGoogle Scholar
  • 25 Mehler-Wex C, Riederer P, Gerlach M. Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder.  Neurotox Res. 2006;  10 167-179
    CrossrefPubMedGoogle Scholar
  • 26 Mehler-Wex C, Kölch M, Kirchheiner J. et al . Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy.  Child and AdolescPsychiatry Ment Health. 2009;  3 14
    PubMedGoogle Scholar
  • 27 Nock MK, Kazdin AE, Hiripi E. et al . Lifetime prevalence, correlates, and persistence of oppositional defiant disorder: Results from the National Comorbidity Survey Replication.  J Child Psychol Psychiatry. 2007;  48 703-713
    CrossrefPubMedGoogle Scholar
  • 28 Olesen O, Licht R, Thomsen E. et al . Serum concentrations and side effects in psychiatric patients during risperidone therapy.  Therapeutic Drug Monitoring. 1998;  20 380-384
    CrossrefPubMedGoogle Scholar
  • 29 Pappadopulos E, Woolston S, Chait A. et al . Pharmacotherapy of aggression in children and adolescents: Efficacy and effect size.  Can Acad Child Adolesc Psychiatry. 2006;  15 27-39
    PubMedGoogle Scholar
  • 30 Ricci LA, Connor DF, Morrison R. et al . Risperidone exerts potent anti-aggressive effects in a developmentally immature animal model of escalated aggression.  Biol Psychiatry. 2007;  62 218-225
    CrossrefPubMedGoogle Scholar
  • 31 Schwartzer JJ, Connor DF, Morrison RL. et al . Repeated risperidone administration during puberty prevents the generation of the aggressive phenotype in a developmentally immature animal model of escalated aggression.  Physiol Behav. 2008;  95 176-181
    CrossrefPubMedGoogle Scholar
  • 32 Snyder R, Turgay A, Aman M. et al . Risperidone Conduct Study Group. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs.  J Am Acad Child Adolesc Psychiatry. 2002;  41 1026-1036
    CrossrefPubMedGoogle Scholar
  • 33 Turgay A, Binder C, Snyder R. et al . Long-term safety and efficacy of risperidone for the treatment of disruptive behaviour disorders in children with subaverage IQs.  Pediatrics. 2002;  110 34
    CrossrefPubMedGoogle Scholar

Correspondence

Dr. med. K. Klampfl

Department of Child and Adolescent Psychiatry Psychosomatics and Psychotherapy

University of Wuerzburg

Fuechsleinstraße 15

97080 Würzburg

Germany

Phone: +49/931/201 78010

Fax: +49/931/201 78040

Email: klampfl@kjp.uni-wuerzburg.de

      >